Magle Chemoswed Holding AB (publ) hereby announces that the company has entered into an agreement with Redeye AB (“Redeye”) regarding the service as a Certified Adviser. Redeye will be appointed Certified Adviser (CA) on January 12, 2026. Up until then, Vator Securities will continue to act as Certified.
Contact Justin
Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com
Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.
Attachments
Magle Chemoswed Holding AB announces change of Certified Adviser to Redeye
© Modular Finance, source Nordic Press Releases